- UBE2I (Ubiquitin-conjugating enzyme E2 I), also known as Ubc9, is a unique member of the E2 enzyme family because it does not conjugate ubiquitin itself, but rather catalyzes the transfer of SUMO (Small Ubiquitin-like Modifier) proteins to substrates in a process called SUMOylation. This post-translational modification is structurally related to ubiquitination but has distinct cellular functions, typically altering protein localization, stability, activity, or interactions rather than targeting them for degradation.
- UBE2I acts as the sole E2-conjugating enzyme in the SUMO pathway, making it indispensable for the entire SUMOylation system. The SUMO cycle begins with SUMO activation by an E1-activating enzyme, after which SUMO is transferred to UBE2I. UBE2I then collaborates with SUMO-specific E3 ligases (such as members of the PIAS family) to attach SUMO to target lysine residues on substrate proteins, often within a consensus motif (Ψ-K-x-D/E, where Ψ is a hydrophobic residue). Although E3 ligases increase substrate specificity, UBE2I itself can directly catalyze SUMO conjugation without strict dependence on an E3 partner, highlighting its intrinsic catalytic versatility.
- Functionally, UBE2I-SUMOylation regulates a wide range of cellular processes. It plays a central role in nuclear transport, chromatin remodeling, transcriptional regulation, DNA repair, and cell cycle progression. For instance, SUMOylation of transcription factors can repress or activate gene expression by modifying their stability or subcellular localization. In DNA damage response, UBE2I-mediated SUMOylation helps recruit repair proteins to sites of damage, thus maintaining genome integrity. SUMOylation also influences stress responses and apoptosis, positioning UBE2I as a global regulator of cell fate.
- Clinically, dysregulation of UBE2I and the SUMOylation pathway has been linked to cancer, neurodegenerative diseases, and viral infections. In cancer, aberrant SUMOylation can enhance tumor cell survival, proliferation, and resistance to therapy. Overexpression of UBE2I has been reported in several cancers, including breast, prostate, and lung tumors, where it correlates with poor prognosis. In neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease, altered SUMOylation of aggregation-prone proteins may contribute to disease progression. Viruses, including HIV and herpesviruses, exploit the SUMOylation system to modify host proteins, evade immune responses, and enhance viral replication.
- Structurally, UBE2I resembles ubiquitin-conjugating enzymes, containing the ubiquitin-conjugating (UBC) catalytic fold with a central active-site cysteine residue that forms a thioester intermediate with SUMO. Despite this structural similarity, its substrate repertoire and biological impact are distinct due to its specialization for SUMO conjugation. Importantly, because it is the only E2 in the SUMO pathway, UBE2I is a potential therapeutic target: inhibitors of UBE2I could broadly suppress SUMOylation and may be useful in treating cancers or viral infections where SUMO modification is hijacked.
- In summary, UBE2I (Ubc9) is the exclusive E2 enzyme for SUMO conjugation, making it essential for SUMOylation and its widespread regulatory functions. By modifying hundreds of proteins, UBE2I influences transcription, DNA repair, stress responses, and cell cycle control. Its dysregulation contributes to cancer, neurodegeneration, and infection, and its central role in the SUMO pathway makes it a particularly attractive drug target.
Reliability Index *****
Note: If you notice any errors or inconsistencies, we welcome your feedback. Please share your observations in the comment box below — your input helps us improve.
Highest reliability: *****
Lowest reliability: *****
